ArticleMovement disorders : official journal of the Movement Disorder Society2020
Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
Article in Movement disorders : official journal of the Movement Disorder Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Electrophysiological Brain Connectivity and Subjective States Evoked by Electrical Stimulation of the Human Mid-thalamus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Atherosclerotic-dose TMAO accentuates redox imbalances and motor dysfunctions in a MPTP mouse model of Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson's disease model.NPJ Parkinson's disease · 2024Article
- Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates.NPJ Parkinson's disease · 2024Article
- Review on allosteric modulators of dopamine receptors so far.Health science reports · 2024Article
- Evidence for direct dopaminergic connections between substantia nigra pars compacta and thalamus in young healthy humans.Frontiers in neural circuits · 2024Article
- Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Variable cardiac responses in rhesus macaque monkeys after discrete mediodorsal thalamus manipulations.Scientific reports · 2023Article
- Mapping the primate thalamus: systematic approach to analyze the distribution of subcortical neuromodulatory afferents.Brain structure & function · 2023Article
- Connectivity of corticostriatal circuits in nonmanifesting LRRK2 G2385R and R1628P carriers.CNS neuroscience & therapeutics · 2022Article
- Allosteric modulation of dopamine DPharmacological reports : PR · 2022Article
- Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?Nature reviews. Neuroscience · 2022Review
- Benchmarking of tools for axon length measurement in individually-labeled projection neurons.PLoS computational biology · 2021Article
- Analysis of morphological and neurochemical changes in subthalamic nucleus neurons in response to a unilateral 6-OHDA lesion of the substantia nigra in adult rats.IBRO neuroscience reports · 2021Article
- A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity.International journal of molecular sciences · 2021Article
- Molecular targets for endogenous glial cell line-derived neurotrophic factor modulation in striatal parvalbumin interneurons.Brain communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDopamine loss beyond the mesostriatal system might be relevant in pathogenic mechanisms and some clinical manifestations in PD. The primate thalamus is densely and heterogeneously innervated with dopaminergic axons, most of which express the dopamine transporter, as does the nigrostriatal system. We hypothesized that dopamine depletion may be present in the thalamus of the parkinsonian brain and set out to ascertain possible regional differences.
methodsThe toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was administered to adult macaque monkeys using a slow intoxication protocol. The treated macaques were classified into 2 groups according to their motor status: nonsymptomatic and parkinsonian. Dopamine innervation was studied with immunohistochemistry for the dopamine transporter. Topographic maps of the dopamine transporter-immunoreactive axon distribution were generated and the total length and length density of these axons stereologically estimated using a 3-dimensional fractionator.
resultsParkinsonian macaques exhibited lower dopamine transporter-immunoreactive axon length density than controls in mediodorsal and centromedian-parafascicular nuclei. Dopamine denervation in the mediodorsal nucleus was already noticeable in nonsymptomatic macaques and was even greater in parkinsonian macaques. Reticular nucleus dopamine transporter-immunoreactive axon length density presented an inverse pattern, increasing progressively to the maximum density seen in parkinsonian macaques. No changes were observed in ventral thalamic nuclei. Dopamine transporter-immunoreactive axon maps supported the quantitative findings.
conclusionsChanges in the dopamine innervation of various thalamic nuclei are heterogeneous and start in the premotor parkinsonian stage. These changes may be involved in some poorly understood nonmotor manifestations of PD. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.